Dual business model, incl R&D on proprietary onco and onco-hematology products, and third parties GMP devt and manufacturing services. Owns one of the first authorized cellular therapies (Zalmoxis®, first pt-specific cell therapy for treatment of adult patients affected by leukaemia or other high-risk haematological malignancies) authorized by EMA for all EU Countries, as well as only facility authorized in EU for commercial ex-vivo cell & gene products (Strimvelis and Zalmoxis) manufacturing, serving relevant int'l partners, e.g. GSK, Cellectis, Rocket Pharma et al
Via Olgettina, 58
Milano, LM 20132
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by